Celsis International plc

Industry:	Medical Testing & Clinical Laboratories
Revenues:	$47.4 Million
Employees:	187

Description

Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L).

Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver.

Please contact Jenny Woolway at jwoolway@celsis.com for corporate information.

Products & Services

life sciences products, analytical services, microbial testing, microbial detection, diagnostics

View More Statistics

Site Statistics

Monthly Unique Visitors:	2,503
Site Rank:	481,045
Trust Rating:	Neutral
Stats by

News Archive

Publication No. WO/2009/094597 Published on July 30, Assigned to BioVentures, Celsis International for Nucleic Acid Probe Usage (American Inventors) US Fed News Service, Including US State News; 11/9/2009 ...sequences of interest in a sample. The patent has been assigned to BioVentures Inc., Murfreesboro, Tenn., and Celsis International plc, Chicago. According to an abstract posted by the World Intellectual Property Organization: "The invention... ...more

Chicago-Based Celsis International Goes Private. Investment Weekly News; 10/31/2009 Chicago-based Celsis International, a leading global life sciences...at celsis.com. Keywords: Celsis International, Finance, Financial, Investing...Investment, Private Equity, Celsis International, Finance, Financial, Investing... ...more

Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes. PR Newswire; 10/20/2009 ...BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United...com/ivt for more information. About Celsis International Chicago-based Celsis International is a leading global provider of innovative... ...more